Maze Therapeutics
MAZE
26.25
-0.18
-0.68%
Maze Therapeutics
US · MAZE
#2998 by market cap
Listed 2025
26.25
-0.18
-0.68%
Live - 5344 symbols - heartbeat 314s ago
· 2026-10-08 04:44
Pre-market
26.25
0.00%
After-hours
26.25
0.00%
- Market cap
- 1.46B
- P/E (TTM)i
- -10.91
- P/Bi
- 3.22
- EPSi
- -2.66
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on MAZE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.8 percentage points.
Institutional ownership
- Held by institutions
- 106.30% -2.85pp
- Institutions
- 197 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund46.44%
Mutual Fund38.55%
Hedge Fund19.02%
Public Company1.70%
Individual/Insider0.80%
Private Company0.40%
Government Pension Fund0.16%
Top holders as of 2026-06-30
Third Rock Ventures, LLC
9.77% · 5.42M sh
Frazier Life Sciences Management, LP
9.06% · 5.03M sh
Arch Venture Partners, L.P.
7.42% · 4.12M sh
Deep Track Capital, LP
6.72% · 3.73M sh
BlackRock
6.31% · 3.50M sh
Janus Henderson Group plc
6.14% · 3.41M sh
T. Rowe Price Group, Inc.
4.93% · 2.74M sh
Vanguard Capital Management, LLC
3.60% · 2.00M sh
Logos Global Management, L.P.
3.48% · 1.94M sh
Andreessen Horowitz LLC
3.06% · 1.70M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Jason Coloma | Chief Executive Officer | 0.42% |
| Sekar Kathiresan | Independent Director | 0.19% |
| Atul Dandekar | Chief Strategy & Business Officer | 0.06% |
| Charles Homcy | Chairperson | 0.06% |
| Jonathan Lim | Independent Director | 0.04% |
| Amy Bachrodt | Chief Financial Officer | 0.02% |
| Courtney Phillips | General Counsel | 0.01% |
| Daniel Spiegelman | Independent Director | -- |
| Richard Scheller | Independent Director | -- |
| Paula Johnson | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $27.02–27.02 |
| 2026-09-30 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $10.42–26.93 |
| 2026-09-28 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $10.42–27.06 |
| 2026-09-03 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Automatic Disposition | -9,705 | $26.22 |
| 2026-09-02 | Jason Coloma | Chief Executive Officer | Open Market Disposition | -22,638 | $25.77–27.12 |
| 2026-09-02 | Atul Dandekar | Chief Strategy & Business Officer | Open Market Disposition | -6,434 | $25.81–27.12 |
| 2026-09-02 | Courtney Phillips | General Counsel | Open Market Disposition | -3,993 | $25.78–27.12 |
| 2026-09-02 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Open Market Disposition | -10,295 | $25.78–27.12 |
| 2026-09-01 | Courtney Phillips | General Counsel | Intent to Sell (Form 144) | -4,144 | $26.54 |
| 2026-09-01 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -10,685 | $26.53 |
| 2026-08-31 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $26.29–26.31 |
| 2026-08-31 | Jason Coloma | Chief Executive Officer | Derivative Exercise and Retained | +50,000 | -- |
| 2026-08-31 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Retained | +12,500 | -- |
| 2026-08-31 | Courtney Phillips | General Counsel | Derivative Exercise and Retained | +11,000 | -- |
| 2026-08-31 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $10.42–26.36 |
| 2026-08-31 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +20,000 | -- |
| 2026-08-27 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $10.42–27.58 |
| 2026-08-12 | Paula Johnson | Director | Other Derivative Acquisition | +36,000 | $27.67 |
| 2026-08-12 | Harold Bernstein | President, Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,142 | $10.42–27.61 |
| 2026-08-02 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $26.71–27.09 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:44:40 · For reference only, not investment advice and not tailored to your situation.